Floatz logo

Orm-5029

HER2 Gene Mutation

Orum Therapeutics USA, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the HER2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Capecitabine
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3B
Docetaxel
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Eloxatin
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3B
Neratinib Maleate
Korea University Guro Hospital
Phase 2B
Herzuma
Korea University Guro Hospital
Phase 2B

View all 15 →

Same molecule, other indications

Orm-5029 is also rated in:

HER-2 Gene AmplificationDormant
CC
Indicative ·
43 / 100
View asset →
HER-2 Protein OverexpressionDormant
CC
Indicative ·
43 / 100
View asset →
HER2 positive breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →